NKTX Nkarta, Inc. stock chart & analysis
Conviction 36HealthcareScan · Fri, Nov 6, 2026Nkarta, Inc. (NKTX) closed at $1.73 (+10.19%) on Nov 6, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 42, RS Rating 28, -53.2% from its 52-week high, -5.9% year to date. Sector: Healthcare · Pharmaceutical Preparations.
Financials as of Wed, Sep 30, 2026 · quarterly.
NKTX technical analysis
Trend
NKTX is in a downtrend: price is below the 50-day, which is below the 200-day moving average. It closed 25.6% below the 50-day ($2.34) and 31.0% below the 200-day ($2.52). ADX(14) at 42 points to a strong, established trend. It meets 1 of 8 trend-template criteria.
Momentum
RSI(14) is 42, in the bearish half of its range. MACD crossed above its signal line 2 sessions ago. A bullish RSI divergence is in place. A bullish MACD divergence is in place. Its RS Rating of 28 puts its weighted 12-month performance ahead of about 28% of the US market.
Volume and volatility
Volume on the latest session ran 0.8× its 20-day average. It trades about $2.1M a day on average. ATR(14) is $0.1527, 8.8% of price — its typical daily range. On-balance volume is trending down. Chaikin Money Flow (-0.32) shows distribution.
Key levels
The chart pattern's support is $1.53 and its resistance $2.43. The 52-week range is $1.48 to $3.72; price is 53.2% below the high and 17.6% above the low. The VWAP anchored at the 52-week high is $2.29, above price.
Performance
NKTX returned +11.5% (1 week), -21.6% (1 month), -29.3% (3 months), -45.5% (6 months), -10.8% (1 year), -5.9% (year to date).
About Nkarta, Inc.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
Pharmaceutical Preparations · Listed 2020 · 108 employees
Insider activity
SEC Form 4 transactions in NKTX · open-market 1 sell
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
HASTINGS PAUL J Chief Executive Officer · Common Stock · 2026-06-18 | Sell | 1.78K | $5K | 2026-06-18 | 2026-06-22 |
SEC filings
EDGAR filings in NKTX · 6 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.